Trial Profile
Phase I study of NC-6004 in patients with Head and Neck cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Jan 2017
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- 21 Dec 2016 Status changed from recruiting to discontinued, according to a NanoCarrier media release.
- 29 Jul 2016 New trial record